- Home
- DCI vs PCVX Comparison
DCI vs PCVX Comparison
Compare DCI & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCI
- PCVX
- Stock Information
- Founded
- DCI 1915
- PCVX 2013
- Country
- DCI United States
- PCVX United States
- Employees
- DCI N/A
- PCVX N/A
- Industry
- DCI Pollution Control Equipment
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- DCI Industrials
- PCVX Health Care
- Exchange
- DCI Nasdaq
- PCVX Nasdaq
- Market Cap
- DCI 7.9B
- PCVX 4.4B
- IPO Year
- DCI 1987
- PCVX 2020
- Fundamental
- Price
- DCI $69.35
- PCVX $32.94
- Analyst Decision
- DCI Hold
- PCVX Strong Buy
- Analyst Count
- DCI 4
- PCVX 10
- Target Price
- DCI $70.00
- PCVX $136.50
- AVG Volume (30 Days)
- DCI 628.0K
- PCVX 1.5M
- Earning Date
- DCI 06-03-2025
- PCVX 08-05-2025
- Dividend Yield
- DCI 1.72%
- PCVX N/A
- EPS Growth
- DCI N/A
- PCVX N/A
- EPS
- DCI 2.99
- PCVX N/A
- Revenue
- DCI $3,645,600,000.00
- PCVX N/A
- Revenue This Year
- DCI $3.11
- PCVX N/A
- Revenue Next Year
- DCI $3.41
- PCVX N/A
- P/E Ratio
- DCI $23.25
- PCVX N/A
- Revenue Growth
- DCI 3.26
- PCVX N/A
- 52 Week Low
- DCI $57.45
- PCVX $27.66
- 52 Week High
- DCI $78.95
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- DCI 53.43
- PCVX 46.08
- Support Level
- DCI $68.80
- PCVX $32.06
- Resistance Level
- DCI $69.62
- PCVX $33.81
- Average True Range (ATR)
- DCI 0.90
- PCVX 1.23
- MACD
- DCI -0.06
- PCVX -0.12
- Stochastic Oscillator
- DCI 53.98
- PCVX 19.86
About DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts (including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors). The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.6 billion in revenue and $544 million in operating income in its fiscal 2024.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.